FI85013C - Foerfarande foer framstaellning av antiarteriosklerotiska substituerade karbamidderivat. - Google Patents
Foerfarande foer framstaellning av antiarteriosklerotiska substituerade karbamidderivat. Download PDFInfo
- Publication number
- FI85013C FI85013C FI830247A FI830247A FI85013C FI 85013 C FI85013 C FI 85013C FI 830247 A FI830247 A FI 830247A FI 830247 A FI830247 A FI 830247A FI 85013 C FI85013 C FI 85013C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- case
- urea
- reacted
- same
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 44
- -1 aryl isocyanate Chemical class 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 21
- 150000003335 secondary amines Chemical class 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 150000004982 aromatic amines Chemical class 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000012948 isocyanate Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 30
- 239000000203 mixture Substances 0.000 description 27
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 24
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 235000013877 carbamide Nutrition 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 15
- 239000000543 intermediate Substances 0.000 description 14
- 239000004202 carbamide Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 238000009825 accumulation Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 201000001320 Atherosclerosis Diseases 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 150000003672 ureas Chemical class 0.000 description 8
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000000010 aprotic solvent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- BQIRPLYKNRXSMI-UHFFFAOYSA-N 1-[(4-butylphenyl)methyl]-3-(2,4-dichlorophenyl)-1-heptylurea Chemical compound C=1C=C(Cl)C=C(Cl)C=1NC(=O)N(CCCCCCC)CC1=CC=C(CCCC)C=C1 BQIRPLYKNRXSMI-UHFFFAOYSA-N 0.000 description 3
- AZHKELKHBWQIMI-UHFFFAOYSA-N 1-[(4-butylphenyl)methyl]-3-(4-chloro-2-methylphenyl)-1-heptylurea Chemical compound C=1C=C(Cl)C=C(C)C=1NC(=O)N(CCCCCCC)CC1=CC=C(CCCC)C=C1 AZHKELKHBWQIMI-UHFFFAOYSA-N 0.000 description 3
- ZSUBZLUMQRVHST-UHFFFAOYSA-N 1-benzyl-1-butyl-3,3-diphenylurea Chemical compound C=1C=CC=CC=1N(C=1C=CC=CC=1)C(=O)N(CCCC)CC1=CC=CC=C1 ZSUBZLUMQRVHST-UHFFFAOYSA-N 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 3
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- SCTIMGJRCLALDJ-UHFFFAOYSA-N n-[[4-(3-methylbutyl)phenyl]methyl]heptan-1-amine Chemical compound CCCCCCCNCC1=CC=C(CCC(C)C)C=C1 SCTIMGJRCLALDJ-UHFFFAOYSA-N 0.000 description 3
- IWFYZVFKBNNZHX-UHFFFAOYSA-N n-benzyl-n-butylcarbamoyl chloride Chemical compound CCCCN(C(Cl)=O)CC1=CC=CC=C1 IWFYZVFKBNNZHX-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GKEHHLJOYZDXMI-UHFFFAOYSA-N (2,4-dimethylphenyl)urea Chemical compound CC1=CC=C(NC(N)=O)C(C)=C1 GKEHHLJOYZDXMI-UHFFFAOYSA-N 0.000 description 2
- KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QDWYQFLKWCSOMI-UHFFFAOYSA-N 1-[(4-butylphenyl)methyl]-1-heptyl-3-(2,4,5-trichlorophenyl)urea Chemical compound C=1C(Cl)=C(Cl)C=C(Cl)C=1NC(=O)N(CCCCCCC)CC1=CC=C(CCCC)C=C1 QDWYQFLKWCSOMI-UHFFFAOYSA-N 0.000 description 2
- WXIZNHAOABRKPH-UHFFFAOYSA-N 1-[(4-butylphenyl)methyl]-1-heptyl-3-(2,4,6-trichlorophenyl)urea Chemical compound ClC=1C=C(Cl)C=C(Cl)C=1NC(=O)N(CCCCCCC)CC1=CC=C(CCCC)C=C1 WXIZNHAOABRKPH-UHFFFAOYSA-N 0.000 description 2
- BJZOVNPMARBZNU-UHFFFAOYSA-N 1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptyl-3-(2,4,6-trifluorophenyl)urea Chemical compound FC=1C=C(F)C=C(F)C=1NC(=O)N(CCCCCCC)CC1=CC=C(CC(C)(C)C)C=C1 BJZOVNPMARBZNU-UHFFFAOYSA-N 0.000 description 2
- ZGBBSERQQNWUKG-UHFFFAOYSA-N 1-butyl-3-(2,4-dimethylphenyl)-1-[(4-methylphenyl)methyl]urea Chemical compound C=1C=C(C)C=C(C)C=1NC(=O)N(CCCC)CC1=CC=C(C)C=C1 ZGBBSERQQNWUKG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 150000002185 fatty acyl-CoAs Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- VLJJFRIHSLTXSI-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NCC=2C(=CC=CC=2)Cl)=C1 VLJJFRIHSLTXSI-UHFFFAOYSA-N 0.000 description 2
- PUEUFOKKVOOXEW-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]butan-1-amine Chemical compound CCCCNCC1=CC=CC=C1Cl PUEUFOKKVOOXEW-UHFFFAOYSA-N 0.000 description 2
- RLMPWGAJKNLQIO-UHFFFAOYSA-N n-[[4-(2,2-dimethylpropyl)phenyl]methyl]heptan-1-amine Chemical compound CCCCCCCNCC1=CC=C(CC(C)(C)C)C=C1 RLMPWGAJKNLQIO-UHFFFAOYSA-N 0.000 description 2
- HIPXPABRMMYVQD-UHFFFAOYSA-N n-benzylbutan-1-amine Chemical compound CCCCNCC1=CC=CC=C1 HIPXPABRMMYVQD-UHFFFAOYSA-N 0.000 description 2
- PERRBGDAOVSLIV-UHFFFAOYSA-N n-butyl-2-chlorobenzamide Chemical compound CCCCNC(=O)C1=CC=CC=C1Cl PERRBGDAOVSLIV-UHFFFAOYSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 230000004903 negative regulation of intestinal cholesterol absorption Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XNVHLZNMYBIIDA-UHFFFAOYSA-N phenyl n-(2,4,6-trifluorophenyl)carbamate Chemical compound FC1=CC(F)=CC(F)=C1NC(=O)OC1=CC=CC=C1 XNVHLZNMYBIIDA-UHFFFAOYSA-N 0.000 description 2
- UKTDAQDTJFLOMR-UHFFFAOYSA-N phenyl n-(4-chloro-2,6-dimethylphenyl)carbamate Chemical compound CC1=CC(Cl)=CC(C)=C1NC(=O)OC1=CC=CC=C1 UKTDAQDTJFLOMR-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- PODOAIWAYUVDEF-UHFFFAOYSA-N (2,4,6-trichlorophenyl)urea Chemical compound NC(=O)NC1=C(Cl)C=C(Cl)C=C1Cl PODOAIWAYUVDEF-UHFFFAOYSA-N 0.000 description 1
- SBBRRSKIPTXBCO-UHFFFAOYSA-N (2,4-difluorophenyl)urea Chemical compound NC(=O)NC1=CC=C(F)C=C1F SBBRRSKIPTXBCO-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- VNZQNFWZDFXVRY-UHFFFAOYSA-N 1-[(4-butylphenyl)methyl]-1-heptyl-3-(2,4,5-trimethylphenyl)urea Chemical compound C=1C(C)=C(C)C=C(C)C=1NC(=O)N(CCCCCCC)CC1=CC=C(CCCC)C=C1 VNZQNFWZDFXVRY-UHFFFAOYSA-N 0.000 description 1
- RHZPLSCNTZDZFL-UHFFFAOYSA-N 1-[(4-butylphenyl)methyl]-3-(2,4-difluorophenyl)-1-heptylurea Chemical compound C=1C=C(F)C=C(F)C=1NC(=O)N(CCCCCCC)CC1=CC=C(CCCC)C=C1 RHZPLSCNTZDZFL-UHFFFAOYSA-N 0.000 description 1
- MNSXLWQNUVUCPP-UHFFFAOYSA-N 1-[(4-butylphenyl)methyl]-3-(2,4-difluorophenyl)urea Chemical compound C(CCC)C1=CC=C(CNC(=O)NC2=C(C=C(C=C2)F)F)C=C1 MNSXLWQNUVUCPP-UHFFFAOYSA-N 0.000 description 1
- VEIKVCBDZNZGPY-UHFFFAOYSA-N 1-[(4-butylphenyl)methyl]-3-(2,4-dimethylphenyl)-1-heptylurea Chemical compound C=1C=C(C)C=C(C)C=1NC(=O)N(CCCCCCC)CC1=CC=C(CCCC)C=C1 VEIKVCBDZNZGPY-UHFFFAOYSA-N 0.000 description 1
- CQCRPHVZWXLSLZ-UHFFFAOYSA-N 1-benzyl-1-butyl-3-(2,4-dimethylphenyl)urea Chemical compound C=1C=C(C)C=C(C)C=1NC(=O)N(CCCC)CC1=CC=CC=C1 CQCRPHVZWXLSLZ-UHFFFAOYSA-N 0.000 description 1
- JKXLTTZJKQMKLA-UHFFFAOYSA-N 1-benzyl-1-butyl-3-(3-chlorophenyl)-3-phenylurea Chemical compound C=1C=CC=CC=1N(C=1C=C(Cl)C=CC=1)C(=O)N(CCCC)CC1=CC=CC=C1 JKXLTTZJKQMKLA-UHFFFAOYSA-N 0.000 description 1
- ATEBHIRYVNQWLR-UHFFFAOYSA-N 1-butyl-1-[(4-tert-butylphenyl)methyl]-3-(2,4-dimethylphenyl)urea Chemical compound C=1C=C(C)C=C(C)C=1NC(=O)N(CCCC)CC1=CC=C(C(C)(C)C)C=C1 ATEBHIRYVNQWLR-UHFFFAOYSA-N 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- QUOBVYPFBJUOAJ-UHFFFAOYSA-N 1-isocyanato-2,4-dimethylbenzene Chemical compound CC1=CC=C(N=C=O)C(C)=C1 QUOBVYPFBJUOAJ-UHFFFAOYSA-N 0.000 description 1
- BJSVKBGQDHUBHZ-UHFFFAOYSA-N 2,4,6-trifluoroaniline Chemical compound NC1=C(F)C=C(F)C=C1F BJSVKBGQDHUBHZ-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- DQASKCHMOLIVGW-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-1-heptyl-1-[[4-(3-methylbutyl)phenyl]methyl]urea Chemical compound C=1C=C(F)C=C(F)C=1NC(=O)N(CCCCCCC)CC1=CC=C(CCC(C)C)C=C1 DQASKCHMOLIVGW-UHFFFAOYSA-N 0.000 description 1
- CIDIAEUJFUABCA-UHFFFAOYSA-N 3-(4-chloro-2,6-dimethylphenyl)-1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptylurea Chemical compound CC=1C=C(Cl)C=C(C)C=1NC(=O)N(CCCCCCC)CC1=CC=C(CC(C)(C)C)C=C1 CIDIAEUJFUABCA-UHFFFAOYSA-N 0.000 description 1
- LEGPZHPSIPPYIO-UHFFFAOYSA-N 3-Methoxyphenylacetic acid Chemical compound COC1=CC=CC(CC(O)=O)=C1 LEGPZHPSIPPYIO-UHFFFAOYSA-N 0.000 description 1
- OHHIBZKYXJDQEU-UHFFFAOYSA-N 3-chloro-n-phenylaniline Chemical compound ClC1=CC=CC(NC=2C=CC=CC=2)=C1 OHHIBZKYXJDQEU-UHFFFAOYSA-N 0.000 description 1
- 125000003352 4-tert-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- APPSFWZTKFBCHL-UHFFFAOYSA-N 5-chloro-2-isocyanato-1,3-dimethylbenzene Chemical compound CC1=CC(Cl)=CC(C)=C1N=C=O APPSFWZTKFBCHL-UHFFFAOYSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- UHRJIHADNMITQE-UHFFFAOYSA-N C(C1=CC=CC=C1)N(C(=O)N(C1=CC=CC=C1)C1=CC(=CC=C1)Cl)CCCC.C(C1=CC=CC=C1)NCCCC Chemical compound C(C1=CC=CC=C1)N(C(=O)N(C1=CC=CC=C1)C1=CC(=CC=C1)Cl)CCCC.C(C1=CC=CC=C1)NCCCC UHRJIHADNMITQE-UHFFFAOYSA-N 0.000 description 1
- ZNHGSJFUMJGHFO-UHFFFAOYSA-N C1(=CC=CC=C1)NC1=CC(=CC=C1)Cl.C(C1=CC=CC=C1)N(C(=O)N(C1=CC=CC=C1)C1=CC(=CC=C1)Cl)CCCC Chemical compound C1(=CC=CC=C1)NC1=CC(=CC=C1)Cl.C(C1=CC=CC=C1)N(C(=O)N(C1=CC=CC=C1)C1=CC(=CC=C1)Cl)CCCC ZNHGSJFUMJGHFO-UHFFFAOYSA-N 0.000 description 1
- OLVFZBIQSKBCDB-UHFFFAOYSA-N COC=1C=C(C=CC1)CC(=O)O.ClC1=C(CNC(CC2=CC(=CC=C2)OC)=O)C=CC=C1 Chemical compound COC=1C=C(C=CC1)CC(=O)O.ClC1=C(CNC(CC2=CC(=CC=C2)OC)=O)C=CC=C1 OLVFZBIQSKBCDB-UHFFFAOYSA-N 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- FTAMHZHVXNVAKM-UHFFFAOYSA-N ClC1=CC(=C(C(=C1)C)NC(N(CCCCCCC)CC1=CC=C(C=C1)CC(C)(C)C)=O)C.FC1=C(C=CC(=C1)F)NC(N(CCCCCCC)CC1=CC=C(C=C1)CC(C)(C)C)=O Chemical compound ClC1=CC(=C(C(=C1)C)NC(N(CCCCCCC)CC1=CC=C(C=C1)CC(C)(C)C)=O)C.FC1=C(C=CC(=C1)F)NC(N(CCCCCCC)CC1=CC=C(C=C1)CC(C)(C)C)=O FTAMHZHVXNVAKM-UHFFFAOYSA-N 0.000 description 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MGYYPGVDFNPEJL-UHFFFAOYSA-N N-chloro-2,6-dimethylaniline Chemical compound CC1=CC=CC(C)=C1NCl MGYYPGVDFNPEJL-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000003619 algicide Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- VVUAADACTIQHDR-UHFFFAOYSA-N n-(3-chlorophenyl)-n-phenylcarbamoyl chloride Chemical compound C=1C=CC(Cl)=CC=1N(C(=O)Cl)C1=CC=CC=C1 VVUAADACTIQHDR-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- XDUHQPOXLUAVEE-BPMMELMSSA-N oleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 XDUHQPOXLUAVEE-BPMMELMSSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- YLLIGHVCTUPGEH-UHFFFAOYSA-M potassium;ethanol;hydroxide Chemical compound [OH-].[K+].CCO YLLIGHVCTUPGEH-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004360 trifluorophenyl group Chemical group 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
- C07C273/1818—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety from -N=C=O and XNR'R"
- C07C273/1827—X being H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34269382 | 1982-01-26 | ||
| US06/342,698 US4387105A (en) | 1982-01-26 | 1982-01-26 | Methods of treating atherosclerosis with dialkylureas and dialkylthioureas |
| US06/342,693 US4473579A (en) | 1982-01-26 | 1982-01-26 | Antiatherosclerotic tetrasubstituted ureas and thioureas |
| US34269882 | 1982-01-26 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI830247A0 FI830247A0 (fi) | 1983-01-25 |
| FI830247L FI830247L (fi) | 1983-07-27 |
| FI85013B FI85013B (fi) | 1991-11-15 |
| FI85013C true FI85013C (fi) | 1992-02-25 |
Family
ID=26993144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI830247A FI85013C (fi) | 1982-01-26 | 1983-01-25 | Foerfarande foer framstaellning av antiarteriosklerotiska substituerade karbamidderivat. |
Country Status (20)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2138804A (en) * | 1983-04-27 | 1984-10-31 | Sumitomo Chemical Co | Fungicidal N-phenylcarbamates |
| GB2149394B (en) * | 1983-07-19 | 1986-09-24 | American Cyanamid Co | Ureas |
| US4818899A (en) * | 1986-12-03 | 1989-04-04 | Minnesota Mining And Manufacturing Company | Second harmonic generation by carbamic acid derivatives |
| EP0344425B1 (en) * | 1988-03-30 | 1993-12-08 | Warner-Lambert Company | N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents |
| US5116848A (en) * | 1988-03-30 | 1992-05-26 | Warner-Lambert Company | N-(((2,6-disubstituted)phenyl)-n-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic agents |
| EP0515684A4 (en) * | 1990-02-14 | 1993-04-21 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of denatured ldl formation |
| US5668136A (en) * | 1990-09-25 | 1997-09-16 | Eisai Co., Ltd. | Trisubstituted benzene derivatives, composition and methods of treatment |
| HUT62558A (en) * | 1991-07-01 | 1993-05-28 | Sandoz Ag | Process for producing n-phenylthiourea derivaties and pharmaceutical compositions comprising same |
| CA2115915A1 (en) * | 1992-07-20 | 1994-02-03 | Kenji Hayashi | Benzene derivatives |
| AU8534198A (en) * | 1997-08-05 | 1999-03-01 | Novo Nordisk A/S | Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use |
| TW415942B (en) * | 1997-09-03 | 2000-12-21 | American Home Prod | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents |
| US6455566B1 (en) | 1997-09-03 | 2002-09-24 | Wyeth | Substituted 1-aryl-3-heteroaryl-thioureas (or isothioureas) as antiatherosclerotic agents |
| WO1999037604A2 (en) * | 1998-01-21 | 1999-07-29 | Zymogenetics, Inc. | Dialkyl ureas as calcitonin mimetics |
| CA2692598A1 (en) * | 2007-07-10 | 2009-01-15 | Amgen Inc. | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL92838C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1949-12-06 | |||
| US2688039A (en) * | 1952-02-08 | 1954-08-31 | Ciba Pharm Prod Inc | Halogen-containing di-(substituted phenyl)-thioureas |
| US3326663A (en) * | 1964-09-25 | 1967-06-20 | Shell Oil Co | Herbicidal phenylureas |
| US3335142A (en) * | 1965-07-07 | 1967-08-08 | American Cyanamid Co | Process for the preparation of n, n'-disubstituted ureas |
| US3659012A (en) * | 1969-05-26 | 1972-04-25 | Lilly Co Eli | Methods of treating helminth infections with thiourea derivatives |
| US3728386A (en) * | 1970-07-27 | 1973-04-17 | Exxon Research Engineering Co | N-cycloalkylalkyl and n-cycloalkyl substituted phenyl ureas and halo acetamides |
| US3928437A (en) * | 1970-09-02 | 1975-12-23 | Ciba Geigy Corp | Phenoxy-phenyl, phenylthiophenyl, phenylsulfonylphenyl and phenylaminophenyl diaminothioureas |
| US3856952A (en) * | 1973-03-01 | 1974-12-24 | Pennwalt Corp | Synergistic antimicrobial compositions employing certain n-(phenyl-carbamyl)amino-benzene sulfonyl flourides |
| US3903130A (en) * | 1974-05-03 | 1975-09-02 | Stauffer Chemical Co | 1-Trifluormethylphenyl-3-dicyanophenyl urea |
| DE2928485A1 (de) * | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
-
1982
- 1982-12-05 IL IL67417A patent/IL67417A/xx not_active IP Right Cessation
- 1982-12-22 DE DE19823247581 patent/DE3247581A1/de not_active Withdrawn
- 1982-12-28 KR KR8205843A patent/KR890001808B1/ko not_active Expired
-
1983
- 1983-01-14 GR GR70261A patent/GR77186B/el unknown
- 1983-01-21 AU AU10681/83A patent/AU562699B2/en not_active Ceased
- 1983-01-24 GB GB08301863A patent/GB2113684B/en not_active Expired
- 1983-01-25 NL NL8300269A patent/NL8300269A/nl not_active Application Discontinuation
- 1983-01-25 IE IE146/83A patent/IE54683B1/en not_active IP Right Cessation
- 1983-01-25 DK DK028683A patent/DK160869C/da not_active IP Right Cessation
- 1983-01-25 PT PT76138A patent/PT76138A/pt not_active IP Right Cessation
- 1983-01-25 PL PL1983240284A patent/PL143836B1/pl unknown
- 1983-01-25 SE SE8300370A patent/SE462653B/sv not_active IP Right Cessation
- 1983-01-25 NO NO830238A patent/NO158417C/no unknown
- 1983-01-25 FI FI830247A patent/FI85013C/fi not_active IP Right Cessation
- 1983-01-25 CH CH404/83A patent/CH654571A5/de not_active IP Right Cessation
- 1983-01-25 ES ES519246A patent/ES519246A0/es active Granted
- 1983-01-25 HU HU83227A patent/HU200746B/hu not_active IP Right Cessation
- 1983-01-25 AT AT0023983A patent/AT391313B/de not_active IP Right Cessation
- 1983-01-25 FR FR8301082A patent/FR2521134B1/fr not_active Expired
- 1983-01-25 IT IT47605/83A patent/IT1203647B/it active
-
1984
- 1984-04-11 ES ES531508A patent/ES531508A0/es active Granted
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI85013C (fi) | Foerfarande foer framstaellning av antiarteriosklerotiska substituerade karbamidderivat. | |
| US4387106A (en) | Method of treating atherosclerosis with di(aralkyl)ureas and di(aralkyl)thioureas | |
| US4473579A (en) | Antiatherosclerotic tetrasubstituted ureas and thioureas | |
| US4387105A (en) | Methods of treating atherosclerosis with dialkylureas and dialkylthioureas | |
| JPH06501706A (ja) | アミノスルホニルカルバメート | |
| US4397868A (en) | Method of treating atherosclerosis with trisubstituted ureas | |
| US4460607A (en) | Lipid absorption-inhibiting agents and their use | |
| EP0194464B1 (en) | Amino acid derivatives and use thereof for the preparation of an anticonvulsant | |
| US4603145A (en) | Antiatherosclerotic diphenyl alkanamides | |
| EP0556322B1 (en) | Aminosulfonyl urea acat inhibitors | |
| HU207843B (en) | Process for producing diurea derivatives and pharmaceutical compositions containing them | |
| CA1239150A (en) | Anti-atherosclerotic trisubstituted ureas | |
| US5126483A (en) | 1-phenylalkyl-3-phenylurea derivatives | |
| CA2010184A1 (en) | Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds | |
| EP0447116B1 (en) | Urea derivatives, their production, and pharmaceutical compositions containing them | |
| EP0439059B1 (en) | 1-Phenylalkyl-3-phenylurea derivative | |
| US4575514A (en) | Anxiety alleviating compositions containing loweralkyl-N-[amino(arylaminocarbonyl)-iminomethyl]-N-methylglycinates | |
| US4994465A (en) | Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds | |
| US3663564A (en) | Urazoles and their production | |
| US5258405A (en) | Urea derivatives and salts thereof in method for inhibiting the ACAT enzyme | |
| JPH06502415A (ja) | オキシスルホニルカルバメート | |
| US4131608A (en) | Thioethers | |
| US5286752A (en) | Antiarrhythmic diarylamidines | |
| US5264559A (en) | Azoxy compounds | |
| CZ280881B6 (cs) | Diaminomethylendioxandionové deriváty |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: AMERICAN CYANAMID COMPANY |